|
|
|
| A study on the efficacy and adverse effects of antiretroviral therapy among 245 cases of HIV/AIDS patients |
| SUN Ming-ze, WANG Jian-yun, CHEN Ji-jun, TAO Lian-di, YU Feng, ZHOU Ying-quan
|
| Clinical Pharmacy Teaching and Research Section, China Pharmaceutical University, Nanjing,210009,China |
|
|
|
|
Abstract Objective To learn the efficacy and adverse effects on HIV/AIDS patients after one year of treatment by highly active antiretroviral therapy (HAART), and to provide data support for antiretroviral therapy.Methods Retrospective study was used in this investigation. A total of 245 cases of HIV/AIDS patients over 16 years old freely receiving anti-AIDS drug treatment at least for one year in Lanzhou Pulmonary Hospital during July 2009 to December 2013 were included in this study. The demographic characteristics, CD4+ T lymphocyte count after 0, 3, 6, 9, 12 months of treatment, viral load, data of adverse reaction were collected to analyze the short-term curative effect and the adverse reaction of HARRT.Results Compared with the baseline, CD4+ T lymphocyte count of patients increased 152/μl after one year of treatment with a higher growth rate in the first three months, and a smooth increase were observed in the following months(P＜0.05).Viral load of 85.84%(188/219) patients were below detection limit after one year treatment. Patients administrated with nevirapine were observed with 46.07%(82/178),32.58%(58/178),26.40%(47/178)respectively incidence of gastrointestinal reaction, hepatic injury and rash. And incidence of central nervous system symptoms was 38.71%(82/178) among patients administrated with efavirenz. Incidence of myelosuppression was 39.39%(24/62) among patients administrated with zidovudine.Conclusion Highly active antiretroviral therapy could significantly increase CD4+T lymphocyte count of HIV/AIDS patients, however, the adverse reactions potentially caused by antiretroviral therapy could not be ignored and frequent clinical monitoring were needed to improve the treatment effect.
|
|
Received: 04 May 2015
Published: 20 December 2017
|
|
|
|
|
|
[1]ZHANG F J, DOU Z H, MA Y, et al. Five-year outcomes of the China nation free antiretroviral treatment program . Ann Int Med, 2009, 151(4): 241-251.
[2]COHEN M S, CHEN Y Q, CAULEY M M, et al. Prevention of HIV-1 with early antiretroviral therapy . N Engl J Med, 2011, 365 (6): 505-493.
[3]中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南.中国临床感染病杂志, 2011, 4(6): 321-330.
[4]张福杰,王建,王福生,等.国家免费艾滋病抗病毒药物治疗手册. 3版.北京:人民卫生出版社, 2012.
[5]余惠芬,贾曼红,韩瑜,等.云南省HIV感染人群应对艾滋病的现状分析.中华疾病控制杂志, 2012, 16(12): 16-17.
[6]陶思铮,白劲松,李重熙,等.高效抗逆转录病毒治疗艾滋病患者临床毒副作用及疗效动态观察.中国皮肤性病学杂志,2015, 29(3): 267-270.
[7]朱志强,姜太一,刘安,等.奈韦拉平和依非韦伦用于抗HIV治疗的的长期疗效和安全性比较.中国艾滋病性病, 2014, 20(11): 809-811.
[8]郑锦雷,杨介者,徐云,等.高效抗逆转录病毒治疗方案的效果评价.浙江预防医学, 2010, 22(1): 5-7.
[9]辅海平,钱一建,孙强,等. 53例艾滋病抗病毒治疗效果评价.浙江预防医学, 2012, 24(3): 13-14.
[10]张京姬,宋静静,李在村,等.北京市731例初治AIDS患者疗效分析.传染病信息, 2014, 27(6): 347-349.
[11]LIMA V D, HARRIGAN P R, SÉNÉCA M, et al.Epidemiology of antiretroviral multiclass resistance.Am J Epidemiol, 2010, 172(4): 460-468.
[12]覃碧云,贺健梅,邹潇白,等.湖南省252例艾滋病患者抗病毒治疗效果及耐药分析.实用预防医学, 2012, 19(7):964-967.
[13]姚世堂,段松,项丽芬,等.云南省德宏州3 014例艾滋病患者接受抗病毒治疗后药物不良反应分析.中国病毒病杂志, 2011, 1(2): 128-134.
[14]刘安,李在村,张辉,等.艾滋病HAART换药原因分析(附138例报告).北京医学, 2013, 35(9):737-739.
[15]覃川,蒋忠胜,温小凤. 214例 HIV/AIDS病人的 HAART不良反应及换药原因分析.中国艾滋病性病, 2014, 20(12): 901-904. |
|
|
|
